Takeda Withdraws Its Marketing Authorisation Application For Ramelteon, Europe
September 25th, 2008 | No Comments | Posted in Medical Information, Sleep / Sleep Disorders / Insomnia
The European Medicines Agency (EMEA) has been formally notified by Takeda Global Research & Development Centre (Europe) Ltd of its decision to withdraw its application for a centralised marketing authorization for the medicine Ramelteon (ramelteon) 4 and 8 mg tablets. Ramelteon was expected to be used for the treatment of primary insomnia in patients aged 18 years or over.
Tags: Insomnia
Sleeping problems
Insomnia information
Sleepin 


